Michael Andrew Chambers net worth and biography

Michael Chambers Biography and Net Worth

Director of Sarepta Therapeutics

Mr. Chambers co-founded Aldevron, based in Fargo, N.D., in 1998, and served as its chief executive officer for more than 20 years before serving as Executive Chairman of the Board until 2021 when Aldevron was acquired by Danaher Corporation. As founder, Mr. Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe. He currently serves on the Board of Directors at Calviri, Inc.

In 2018, Mr. Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs. He earned his bachelor’s degree in biotechnology, microbiology, and chemistry from North Dakota State University.

What is Michael Andrew Chambers' net worth?: The estimated net worth of Michael Andrew Chambers is at least $31.49 million as of August 16th, 2024. Mr. Chambers owns 284,034 shares of Sarepta Therapeutics stock worth more than $31,488,009 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Chambers may own. Learn More about Michael Andrew Chambers' net worth.
How do I contact Michael Andrew Chambers?: The corporate mailing address for Mr. Chambers and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at [email protected]. Learn More on Michael Andrew Chambers' contact information.
Has Michael Andrew Chambers been buying or selling shares of Sarepta Therapeutics?: Michael Andrew Chambers has not been actively trading shares of Sarepta Therapeutics during the last quarter. Most recently, on Friday, August 16th, Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock. The stock was acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company's stock, valued at $38,003,749.20. Learn More on Michael Andrew Chambers' trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 78,532 shares worth more than $11,647,905.42. The most recent insider tranaction occured on August, 30th when CFO Ian Michael Estepan sold 5,985 shares worth more than $822,099.60. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 8/30/2024.

Michael Andrew Chambers Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2024	Buy	37,038	$133.80	$4,955,684.40	284,034
8/14/2023	Buy	9,979	$109.47	$1,092,401.13	246,996
8/10/2023	Buy	34,867	$106.15	$3,701,132.05	213,331
9/14/2022	Buy	57,100	$104.43	$5,962,953.00	108,178
8/19/2022	Buy	46,170	$108.28	$4,999,287.60	51,078

Michael Andrew Chambers Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $113.13

$113.13

50 Day Range

MA: $122.50

$104.54

$132.02

2 Week Range

Now: $113.13

$78.67

$173.25

Volume

8,659 shs

Average Volume

1,228,416 shs

Market Capitalization

$10.81 billion

P/E Ratio

90.50

Dividend Yield

N/A

Beta

0.81

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.